Tumor detection and elimination by a targeted gallium corrole

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 15, 2009, Pages 6105-6110

  Agadjanian, Hasmik ^a   Ma, Jun ^a   Rentsendorj, Altan ^a   Valluripalli, Vinod ^a   Hwang, Jae Youn ^a   Mahammed, Atif ^b   Farkas, Daniel L ^a   Gray, Harry B ^c   Gross, Zeev ^b   Medina Kauwe, Lali K ^a,d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Heregulin; Human epidermal growth factor receptor; In vivo imaging; Porphyrinoids

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GALLIUM; GROWTH FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; ANTIBODY; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; METALLOPORPHYRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; FLUORESCENCE; HEART INJURY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; C57BL MOUSE; DRUG SCREENING; IMMUNOLOGY; METABOLISM; NEOPLASM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; CELL LINE, TUMOR; FEMALE; HUMANS; METALLOPORPHYRINS; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65549135725     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0901531106     Document Type: Article

References (36)

1. Kawasaki ES, Player A (2005) Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine 1:101-109.
2. Wang Z, et al. (2007) Synthesis and biologic properties of hydrophilic sapphyrins, a new class of tumor-selective inhibitors of gene expression. Mol Cancer 6:9.
3. Chowdhary RK, et al. (2003) Correlation of photosensitizer delivery to lipoproteins and efficacy in tumor and arthritis mouse models; comparison of lipid-based and Pluronic P123 formulations. J Pharm Sci 6:198-204.
4. Haber A, et al. (2008) Amphiphilic/bipolar metallocorroles that catalyze the decomposition of reactive oxygen and nitrogen species, rescue lipoproteins from oxidative damage, and attenuate atherosclerosis in mice. Angew Chem Int Ed Engl 16:16.
5. Mahammed A, Gray HB, Weaver JJ, Sorasaenee K, Gross Z (2004) Amphiphilic corroles bind tightly to human serum albumin. Bioconjugate Chem 15:738-746.
6. Agadjanian H, et al. (2006) Specific delivery of corroles to cells via noncovalent conjugates with viral proteins. Pharm Res 23:367-377.
7. Medina-Kauwe LK, Maguire M, Kasahara N, Kedes L (2001) Non-viral gene delivery to human breast cancer cells by targeted Ad5 penton proteins. Gene Ther 8:1753-1761.
8. Han X, Kasahara N, Kan YW (1995) Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 92:9747-9751.
9. Medina-Kauwe LK, Leung V, Wu L, Kedes L (2000) Assessing the binding and endocy-tosis activity of cellular receptors using GFP-ligand fusions. BioTechniques 29:602-609.
10. Medina-Kauwe LK, Chen X (2002) Using GFP-ligand fusions to measure receptor-mediated endocytosis in living cells. Vitamins and Hormones , ed Litwack G (Elsevier Science, San Diego), Vol 65, pp 81-95.
11. Slamon DJ, et al. (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182.
12. Slamon DJ, Clark GM (1988) Amplification of c-erbB-2 and aggressive human breast tumors? Science 240:1795-1798.
13. Brodowicz T, et al. (1997) Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer 73:875-879.
14. Xu FJ, et al. (1997) Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): Increased invasiveness may contribute to poor prognosis. Clin Cancer Res 3:1629-1634.
15. Keefe DL (2002) Trastuzumab-associated cardiotoxicity. Cancer 95:1592-1600.
16. Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28:13-19.
17. Slamon DJ, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
18. Sepp-Lorenzino L, et al. (1996) Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene 12:1679-1687.
19. Hwang JY, et al. (2007) Multimode optical imaging of small animals: Development and applications. Prog Biomed Opt Imaging 8:1-10.
20. Karimi G, Ramezani M, Abdi A (2005) Protective effects of lycopene and tomato extract against doxorubicin-induced cardiotoxicity. Phytother Res 19:912-914.
21. Shuai Y, et al. (2007) Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment. Toxicol Lett 170:66-74.
22. Gahery-Segard H, et al. (1998) Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol 72:2388-2397.
23. Gahery-Segard H, et al. (1997) Humoral immune response to the capsid components of recombinant adenoviruses: Routes of immunization modulate virus-induced Ig subclass shifts. Eur J Immunol 27:653-659.
24. Yang Y, Greenough K, Wilson JM (1996) Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther 3:412-420.
25. Dougherty TJ (1996) A brief history of clinical photodynamic therapy development at Roswell Park Cancer Institute. J Clin Laser Med 14:219-221.
26. Henderson BW, Sumlin AB, Owczarczak BL, Dougherty TJ (1991) Bacteriochlorophyll-a as photosensitizer for photodynamic treatment of transplantable murine tumors. J Photochem Photobiol 10:303-313.
27. Aviezer D, et al. (2000) Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis. Cancer Res 60:2973-2980.
28. Hurley LH (2002) DNA and its associated processes as targets for cancer therapy. Nat Rev 2:188-200.
29. Billingham ME, Mason JW, Bristow MR, Daniels JR (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62:865-872.
30. Bristow MR, et al. (1978) Early anthracycline cardiotoxicity. Am J Med 65:823-832.
31. Sliwkowski MX, et al. (1994) Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269:14661-14665.
32. Goldman R, Levy RB, Peles E, Yarden Y (1990) Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: A mechanism for receptor trans-regulation. Biochemistry 29:11024-11028.
33. Jeschke M, et al. (1995) Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins. Int J Cancer 60:730-739.
34. Hwang JY, et al. (2008) Large field of view scanning fluorescence lifetime imaging system for multi-mode optical imaging of small animals. Prog Biomed Opt Imaging 68590G:1-8.
35. Farkas DL (2003) Invention and commercialization in optical bioimaging. Nat Biotech-nol 21:1269-1271.
36. Hara M, et al. (2003) Transgenic mice with green fluorescent protein-labeled pancreatic beta-cells. Am J Physiol Endocrinol Metab 284:E177-183.